# Safety and Effectiveness of L2-7001 (Interleukin-2) in HIV-Positive Patients Receiving Anti-HIV Therapy

> **NCT00002449** · PHASE1 · UNKNOWN · sponsor: **Chiron Corporation** · enrollment: 212 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Aldesleukin

## Key facts

- **NCT ID:** NCT00002449
- **Lead sponsor:** Chiron Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1999-08
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 212 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002449, "Safety and Effectiveness of L2-7001 (Interleukin-2) in HIV-Positive Patients Receiving Anti-HIV Therapy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00002449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*